31-Oct-2018NewGeneral

Morgans interview with Kazia CEO Dr James Garner

Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.

 

Dr Garner discusses:

  • The timeline for the next milestones for the trial of Cantrixil, a potential drug for recurrent ovarian cancer
  • Why there’s a need for treatments for the brain cancer glioblastoma multiforme, for which Kazia is developing GDC-0084
  • The company’s current cash position and burn rate

SITE BY SPATIAL DESIGN